07:04 AM EDT, 09/08/2025 (MT Newswires) -- Rapport Therapeutics ( RAPP ) said Monday that a phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint.

Results showed "a statistically significant" reduction in long episodes, compared with baseline over the eight-week treatment period, the company said. RAP-219 also showed a "statistically significant and clinically meaningful" reduction in clinical seizures, compared with baseline and was generally well tolerated, Rapport said.

The company intends to advance RAP-219 into two phase 3 trials in Q3 2026. Rapport said it expects to present additional efficacy analyses and 8-week follow-up results next year.

The company's shares were up nearly 167% in recent premarket activity.